Matthew Fell

Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases

Martin Steger, Francesca Tonelli, Genta Ito et al. · eLife · 2016 · 1.1K citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Matthew Fell, Christian Mirescu, Kallol Basu et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 337 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (–)-(1 R, 4 S,5 S,6 S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039)

Matthew Fell, Kjell Svensson, Bryan G. Johnson et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 206 citations

Medicine, Medicinal Chemistry, Pharmacology +11

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity

Jack D. Scott, Duane E. DeMong, Thomas J. Greshock et al. · Journal of Medicinal Chemistry · 2017 · 148 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits

Marco A. S. Baptista, Kalpana Merchant, Ted Barrett et al. · Science Translational Medicine · 2020 · 130 citations

Medicine, Pharmacology, Pharmacotherapy +9